SphingolipidosesE75.3

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Sphingolip(o)idoses are hereditary lipid storage diseases (enzymopathies) and belong to the rare lysosomal storage diseases. Hereditary lysosomal enzyme defects or deficits or defects of the transport or activator proteins lead to a pathological intracellular accumulation of non-degradable lipoids (thesaurismosis). Sphingolipids are important components of membrane structures and play a role in cell proliferation and differentiation. There are several clinical variants of each individual enzyme disorder, almost all of which affect the CNS and often manifest themselves in childhood. Sphingolipidoses are inherited autosomal recessively (except Fabry: X-recessive). Their pathogenesis has only been partially researched so far.

ClassificationThis section has been translated automatically.

The following diseases with dermatological relevance are counted among the sphingolipidoses (see also table 1):

  • Fabry disease
  • M. Gaucher
  • Aspartyl glucosaminuria
  • Niemann-Pick disease
  • M. Farber (disseminated lipogranulomatosis)
  • Beta-mannosidosis
  • Fucosidosis
  • Kanzaki disease
  • GM1-Gangliosidosis
  • Tay-Sachs disease (GM2-Gangliosidose): Beginning in early childhood with cafe-au-lait stains, vitiligo, canities praecox, progressive loss of mental and physical functions (paralysis, dementia, blindness), characteristic ocular fundus changes (grey-white zone around the fovea centralis: "cherry-red spot") Death mostly in the 2-3 years of age. Histology: Balloon-like neurons in the CNS, glial proliferation, demyelination, ganglioside accumulation (GM2: 90-95% vs 5% normal).
  • Further sphingolipidoses (without cutaneous symptoms):
    • Sulfatide lipoidosis (metachromatic leukodystrophy: manifestation mostly before the age of 3 years, but occasionally occurring in adults. Patients usually die at the age of 5 years. The clinical picture begins with gait disturbances and developmental arrest followed by speech impediment, paralysis and other severe neurological deficits).
    • Krabbe's disease (globoidal cell leukodystrophy): Begins in the 4th-6th month of life with degeneration of the white matter; usually leads to death before the 2nd year of life).

Clinical featuresThis section has been translated automatically.

The course of sphingolipidoses is very variable and ranges from very early onset and death in the first years of life to chronic forms on the other hand. Even an enzyme activity reduced to a few percent can compensate for an enzyme deficit and prevent the outbreak of the disease or lead to an attenuated form. In the case of complete deficiency, the severe form occurs. Mostly the CNS is affected, often also the skin. The clinical pictures are characterized by partly unspecific (see below M. Gaucher), partly very characteristic symptoms ( angiokeratomas).

TherapyThis section has been translated automatically.

  • Enzyme replacement therapy: missing enzymes, e.g. ß-glucocerebrosidase in M. Gaucher, are substituted with biotechnologically produced enzymes. Because of the blood-brain barrier, enzyme replacement therapies are limited to non-neural storage diseases (Gaucher, Fabry).
  • Substrate deprivation: Lysosomal substrate flux is reduced by inhibition of sphingolipid anabolism, i.e. biosynthesis. These therapeutic procedures can lead to immunosuppression and formation of toxic metabolites.

ProphylaxisThis section has been translated automatically.

Hereditary sphingolipidosis can be diagnosed in the unborn child by amniocentesis.

TablesThis section has been translated automatically.

Disease

Enzyme defect

Fabry disease

alpha-galactosidase

M. Gaucher

beta-glucosidase

Aspartyl glucosaminuria

Aspartyl glucosaminidase

Niemann-Pick disease

Sphingomyelinase

Beta-mannosidosis

beta-mannosidase

Fucosidosis

alpha-fucosidase

GM1-Gangliosidosis

beta-galactosidase

M. Colouring agent (disseminated lipogranulomatosis)

Ceramidase

Kanzaki disease

alpha-N-acetylgalactosaminidase

LiteratureThis section has been translated automatically.

  1. Delgado A et al (2007) Chemical Tools to Investigate Sphingolipid Metabolism and Functions. ChemMedChem 25: epub

Authors

Last updated on: 29.10.2020